Low grade B-cell non-Hodgkin lymphoma (LBNHL) is usually slow growing and most often incurable. Case 1: A 47-year-old Malay gentleman was diagnosed with relapsed Stage IV Grade 2 Follicular Lymphoma (Follicular lymphoma international prognostic index, FLIPI 2: intermediate risk). He was initially treated with 6 cycles of standard rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) polychemotherapy at first presentation and was in remission for 8 years until he relapsed with new inguinal lymphadenopathy and bone marrow involvement. He was re-treated with 6 cycles of rituximab-bendamustine (R-B), in which he is in complete remission for the past 2 years. Case 2: A 45-year old Malay female presented with previously untreated Stage IV extranodal marginal zone lymphoma of the left pleura with nodal and bone marrow involvement which did not respond adequately to 3 cycles of R-CHOP chemotherapy. Her unilateral pleural effusion was persistent, and she required re-treatment with 4 cycles R-B immunochemotherapy. She is now in complete remission for the past 18 months. Case 3: A 70-year old Malay gentleman was diagnosed with Waldenstrom macroglobulinemia without hyperviscosity syndrome. He was treated with 2 cycles of R-B immunochemotherapy. However, he developed worsening anemia. He was re-treated with 6 cycles of Bortezomib-Rituximab-Dexamethasone (B-R-D) immunochemotherapy, in which he is currently in complete remission for the past 16 months. Case 4: A 59-year-old Malay gentleman diagnosed with Stage IV non-TP53 mutated leukemic phase mantle cell lymphoma achieved complete remission after completing 6 cycles of intensive chemotherapy followed by consolidation autologous stem cell transplant.
Cite this paper
Kasinathan, G. (2020). Series of Low-Grade B-Cell Lymphoma: Follicular Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia and Mantle Cell Lymphoma. Open Access Library Journal, 7, e6759. doi: http://dx.doi.org/10.4236/oalib.1106759.
Swerdlow, S.H., Campo, E., Pileri, S.A., et al. (2016) The 2016 Revision of the World Health Organisation Classification of Lymphoid Neoplasms. Blood, 127, 2375-2390.
Link, B.K. (2018) Transformation of Follicular Lymphoma-Why Does It Happen, and Can It Be Prevented? Best Practise & Research. Clinical Hematology, 31, 49-56.
Sriskandarajah, P. and Dearden, C.E. (2017) Epidemiology and Environmental Aspects of Marginal Zone Lymphomas. Best Practise & Research. Clinical Hematology, 30, 84-91. https://doi.org/10.1016/j.beha.2016.07.002
Xochelli, A., Kalpadakis, C., Gardiner, A., et al. (2014) Clonal B-Cell Lymphocytosis Exhibiting Immunophenotypic Features Consistent with a Marginal-Zone Origin: Is This a Distict Entity? Blood, 123, 1199-1206.
Ott, G., Katzenberger, T., Lohr, A., et al. (2002) Cytomorphologic, Immunohistochemical, and Cytogenetic Profiles of Follicular Lymphoma: 2 Types of Follicular Lymphomagrade 3. Blood, 99, 3806-3812.
Salama, M.E., Lossos, I.S. and Warnke, R.A. (2009) Immunoarchitectural Patterns in Nodal Marginal Zone B-Cell Lymphoma: A Study of 51 Cases. American Journal of Clinical Pathology, 132, 39-49. https://doi.org/10.1309/AJCPZQ1GXBBNG8OG
Vaxman, I., Bernstine, H., Kleinstern, G., Hendin, N., Shimony, S., Domachevsky, L., Gurion, R., Groshar, D., Raanani, P. and Gafter-Gvili, A. (2019) FDG PET/CT as a Diagnostic and Prognostic Tool for the Evaluation of Marginal Zone Lymphoma. Hematological Oncology, 37, 168-175. https://doi.org/10.1002/hon.2578
Ponzoni, M., Kanellis, G., Pouliou E, et al. (2012) Bone Marrow Histopathology in the Diagnostic Evaluation of Splenic Marginal Zone and Splenic Diffuse Red Pulp Small B-Cell Lymphoma: A Reliable Substitute for Spleen Histopathology? The American Journal of Surgical Pathology, 36, 1609-1618.
Owen, R.G., Treon, S.P., Al-Katib, A., et al. (2003) Clinicopathological Definition of Waldenstrom Macroglobulinemia: Consensus Pabnel Recommendations from the Second International Workshop on Waldenstrom Macroglobulinemia. Seminars in Oncology, 30, 110-115.
Pastore, A., Jurinovic, V., Kridel, R., et al. (2015) Integration of Gene Mutations in Risk Prognostification for Patients Receiving First-Line Immunochemotherapy for Follicular Lymphoma: A Retrospective Analysis of a Prospective Clinical Trial and Validation in a Population-Based Registry. The Lancet Oncology, 16, 1111-1122.
Lockmer, S., Ren, W.C., Brodtkorb, M., Østenstad, B., Wahlin, B.E. Pan-Ham- marström, Q. and Kimby, E. (2020) M7-FLIPI Is Not Prognostic in Follicular Lymphoma Patients with First-Line Rituximab Chemo Free Therapy. British Journal of Haematology, 188, 259-267. https://doi.org/10.1111/bjh.16159
Treon, S.P., Xu, L., and Hunter, Z. (2015) MYD88 L265P Mutations and Response to Ibrutinib in Waldenstrom Macroglobulinemia. The New England Journal of Medicine, 373, 584-586. https://doi.org/10.1056/NEJMc1506192
Marcus, R., Imrie, K., Solal-Celogny, P., Catalano, J.V., Dmoszynska, A., Raposo, J.C., Offner, F.C., Gomez-Codina, J., Belch, A., Cunningham, D., Wassner-Fritsch, E. and Stein, G. (2008) Phase III Study of R-CVP Compared with Cyclophosphamide, Vincristine, and Prednisolone Alone in Patients with Previous Untreated Advanced Follicular Lymphoma. Journal of Clinical Oncology, 26, 4579-4586.
Pott, C., Hoster, E., Kehden, B., et al. (2016) Minimal Residual Disease in Patients with Follicular Lymphoma Treated with Obinutuzumab or Rituximab as First-Line Induction Immunochemotherapy and Maintenance in the Phase 3 GALLIUM Study. Blood, 128, 613. https://doi.org/10.1182/blood.V128.22.613.613
Lopez-Guillermo, A., Canales, M.A., Dlouhy, I., et al. (2013) A Randomised Phase II Study Comparing Consolidation with a Single Dose of 90-Yttrium-Ibritumomab- Tiutexan (Zevalin) vs Maintenance with Rituximab Flor Two Years in Patients with Newly Diagnosed Follicular Lymphoma (FL) Responding to R-CHOP. Preliminary Results at 36 Months from Randomisation. Blood, 122, 369.
Montoto, S., Corradini, P., Dreyling, M., Ghielmini, M., Kimby, E., López-Guillermo, A., Mackinnon, S., Marcus, R.E., Salles, G., Schouten, H.C., Sureda, A. and Dreger, P. (2013) Indications for Hematopoietic Stem Cell Transplantation in Patients with Follicular Lymphoma: A Consensus Project of the EBMT-Lymphoma Working Party. Haematologica, 98, 1014-1021. https://doi.org/10.3324/haematol.2013.084723
Ruskone-Fourmestraux, A., Fischbach, W., Aleman, B.M., Boot, H., Du, M.Q., Megraud, F., Montalban, C., Raderer, M., Savio, A. and Wotherspon, A. (2011) EGILS Consensus Report. Gastric Extranodal Marginal Zone B-Cell Lymphoma of MALT. Gut, 60, 747-758. https://doi.org/10.1136/gut.2010.224949
Wirth, A., Gospodarowicz, M., Pintilie, M., et al. (2013) Long-Term Outcome for Gastric Marginal Zone Lymphoma Treated with Radiotherapy: A Retrospective Muti-Center, International Extranodal Lymphoma Study Group Study. Annals of Oncology, 24, 1344-1351. https://doi.org/10.1093/annonc/mds623
Salar, A., Domingo-Domenech, E., Panizo, C., et al. (2017) Long-Term Results of a Phase II Study of Rituximab and Bendamustine for Mucosa Associated Lymphoid Tissue Lymphoma. Blood, 130, 1772-1774.
Kastritis, E., Gavriatopoulou, M., Kyrtsonis, M.C., et al. (2015) Dexamethasone, Rituximab and Cyclophosphamide as Primary Treatment of Waldenstrom Macroglobulinemia: Final Analysis of a Phase 2 Study. Blood, 126, 1392-1394.
Gavriatopoulou, M., Garcia-Sanz, R., Kastritis, E., et al. (2017) BDR in Newly Diagnosed Patients with WM: Final Analysis of a Phase 2 Study after a Minimum Follow-Up of 6 Yrars. Blood, 129, 456-459.
Hermine, O., Hoster, E., Walewski, J., et al. (2016) Addition of High-Dose Cytarabine to Immunochemotherapy Before Autologous Stem-Cell Transplantation in Patients Aged 65 Years or Younger with Mantle Cell Lymphoma: A Randomised, Open Label, Phase 3 Trial of the European Mantle Cell Lymphoma Network. The Lancet, 388, 565-575. https://doi.org/10.1016/S0140-6736(16)00739-X
Woyach, J.A., Furman, R.R., Liu, T.-M., et al. (2014) Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib. The New England Journal of Medicine, 370, 2286-2294. https://doi.org/10.1056/NEJMoa1400029
Bailly, C., Carlier, T., Touzeau, C., Arlicot, N., Kraeber-Bodéré, F., Le Gouill, S. and Bodet-Milin, C. (2019) Interest of FDG-PET in the Management of Mantle Cell Lymphoma. Frontiers of Medicin, 6, 70.
Visco, C., Chiappella, A., Nassi, L., et al. (2017) Rituximab, Bendamustine, and Low Dose Cytarabine as Induction Therapy in Elderly Patients with Mantle Cell Lymphoma: A Multicentre, Phase 2 Trial from Fondazion Italiana Linfomi. The Lancet Haematology, 4, E15-E23. https://doi.org/10.1016/S2352-3026(16)30185-5